BDBM509135 US11364246, Example 1.3::US20200361871A1, Example 1.3

SMILES Oc1ccc(Cl)cc1CC(=O)Nc1ccnc(c1)C(=O)NC12CC3CC(CC(C3)C1)C2

InChI Key

Data  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 509135   

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509135(US20200361871A1, Example 1.3 | US11364246, Example...)
Affinity DataEC50:  240nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
Go to US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509135(US20200361871A1, Example 1.3 | US11364246, Example...)
Affinity DataEC50:  240nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
Go to US Patent